Nishimura, T.; Fujimoto, H.; Okano, T.; Naito, M.; Tsuji, C.; Iwanaka, S.; Sakakura, Y.; Yasuma, T.; D’Alessandro-Gabazza, C.N.; Oomoto, Y.;
et al. Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice? Cancers 2022, 14, 2970.
https://doi.org/10.3390/cancers14122970
AMA Style
Nishimura T, Fujimoto H, Okano T, Naito M, Tsuji C, Iwanaka S, Sakakura Y, Yasuma T, D’Alessandro-Gabazza CN, Oomoto Y,
et al. Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice? Cancers. 2022; 14(12):2970.
https://doi.org/10.3390/cancers14122970
Chicago/Turabian Style
Nishimura, Tadashi, Hajime Fujimoto, Tomohito Okano, Masahiro Naito, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Taro Yasuma, Corina N. D’Alessandro-Gabazza, Yasuhiro Oomoto,
and et al. 2022. "Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?" Cancers 14, no. 12: 2970.
https://doi.org/10.3390/cancers14122970
APA Style
Nishimura, T., Fujimoto, H., Okano, T., Naito, M., Tsuji, C., Iwanaka, S., Sakakura, Y., Yasuma, T., D’Alessandro-Gabazza, C. N., Oomoto, Y., Gabazza, E. C., Kobayashi, T., & Ibata, H.
(2022). Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice? Cancers, 14(12), 2970.
https://doi.org/10.3390/cancers14122970
